The Lymphoma Academic Research Organisation

Recent papers from The Lymphoma Academic Research Organisation

1. Proton pump inhibitors and outcome after axicabtagene ciloleucel for the treatment of non-Hodgkin B-cell lymphoma, a retrospective study with the DESCAR-T registryBone Marrow Transplantation · 2026
2. STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphomaBlood · 2026
3. End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trialBlood Cancer Journal · 2026
4. Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin LymphomaClinical Pharmacology & Therapeutics · 2026
5. 3D ex vivo platform for high‐throughput immunotherapy screening in relapsed/refractory lymphoma patientsHemaSphere · 2026
6. Spatial distribution and factors associated with the seroprevalence of arboviruses in Guinea: a nationwide cross-sectional surveyInternational Journal of Epidemiology · 2026
7. Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trialHaematologica · 2026
8. Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armJournal of Hematology & Oncology · 2026
9. Hemophagocytic lymphohistiocytosis‐like syndrome after CD19‐directed CAR T‐cells for B‐cell lymphoma and B‐cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR‐T registryHemaSphere · 2026
10. Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyHaematologica · 2026
11. Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapseHaematologica · 2026
12. Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA groupHemaSphere · 2026
13. Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experienceHaematologica · 2026
14. Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisBlood · 2026
15. Mediterranean diet preserves renal mitochondrial homeostasis and attenuates early diabetic kidney injury in db/db miceExperimental Gerontology · 2026
16. Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive studyThorax · 2026
17. Abstract DP347: LYS241: A Novel Humanized Antibody Counteracting tPA-Mediated Neurotoxicity and BBB Disruption in StrokeStroke · 2026
18. Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapyBlood Cancer Journal · 2026
19. Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphomaBlood Advances · 2026
20. Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysaBlood · 2025